Mark joins Auron Therapeutics with diverse discovery and translational oncology experience from a number of organizations including Merck, Agios, Dana Farber’s Belfer Center, and most recently, Parthenon Therapeutics. Throughout his industry career, Mark has worked on developing cancer therapies targeting multiple metabolic, epigenetic, and signaling proteins, with his most recent work aimed at targeting the tumor microenvironment of immune-excluded tumors. Mark has additional leadership experience from his role at Sai Life Science where he was the Global Head of Biology leading a multi-site team supporting drug discovery activities for clients across a wide spectrum of biopharma. Mark has BA from Johns Hopkins University and a Ph.D. from the University of Wisconsin-Madison.
About
